SEVERAL FACTORS NEED TO BE CONSIDERED WHEN MAKING TREATMENT DECISIONS IN MS

Appropriate response to the changing needs of every patient demands a flexible treatment strategy that leaves future therapeutic options open. This means that those making treatment decisions should, like chess players, think several moves ahead.

MS – A GAME OF CHESS: PLAY NOW TO WIN A SPECIAL PRIZE!

1) Roll over the chess pieces to find the ones you can move.  

2) Click on the piece you want to select and then on the square you want to move it to – read the messages below the chessboard.

3) Wait for your opponent’s move.

Get to checkmate in 4 moves to download the following publication for free! 

Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351-2374.

Roll over your pieces to find your next move!

To view the content

Please rotate your device

Biogen-99461.
Date of preparation: March 2021.

References:
1. Embrey N. Multiple sclerosis: managing a complex neurological disease. Nurs Stand. 2014;29(11):49-58.
2. Disanto G, Berlanga AJ, Handel AE, et al. Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Dis. 2010;2011:932351.
3. Girouard N, Soucy N. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence. 2011;5:101-108
4. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World J Clin Cases. 2015;3(7):545-555.
5. Lugaresi A, di Ioia M, Travaglini D, et al. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2013;9:893-914.
6. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351-2374.
7. Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: Vaccine preventable infections and immunization in multiple sclerosis. 2019;93(13):584-594.
8. Schweitzer F, Laurent S, Fink GR, et al. Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. Neurol. 2020;doi: 10.1007/s00415-019-09690-6. [Epub ahead of print].
9. National Multiple Sclerosis Society. Available at: https://www.nationalmssociety.org/Living-Well-With-MS/Diet-Exercise-Healthy-Behaviors/Vaccinations. Accessed February 2021.
10. AVONEX (interferon beta-1a) Summary of Product Characteristics. September 2020.
11. PLEGRIDY (peginterferon beta-1a) Summary of Product Characteristics. December 2020.
12. TYSABRI (natalizumab) Summary of Product Characteristics. December 2020.
13. TECFIDERA (dimethyl fumarate) Summary of Product Characteristics. December 2020.